Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2023

Oct 30, 2023

29777_dirs_2023-10-30_850e6f93-a91d-4936-a6d7-8f961a25f05d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-10-26

Reporting Person: STARKS DANIEL J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-10-26 Common shares without par value S 26907 $93.8141 Disposed 6748409 Direct
2023-10-26 Common shares without par value S 23093 $94.3260 Disposed 6725316 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common shares without par value 258 Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.06 to $94.05, inclusive. The
reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission,
upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices
ranging from $94.06 to $94.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
this footnote.

F3: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.